1. Home
  2. PPBT vs RDHL Comparison

PPBT vs RDHL Comparison

Compare PPBT & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.74

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.19

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPBT
RDHL
Founded
2010
2009
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
3.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PPBT
RDHL
Price
$0.74
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
784.3K
69.6K
Earning Date
11-14-2025
09-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,550,000.00
Revenue This Year
N/A
$381.91
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.62
52 Week Low
$0.53
$1.01
52 Week High
$5.20
$7.44

Technical Indicators

Market Signals
Indicator
PPBT
RDHL
Relative Strength Index (RSI) 45.28 49.36
Support Level $0.78 $1.18
Resistance Level $0.87 $1.26
Average True Range (ATR) 0.07 0.05
MACD -0.00 0.03
Stochastic Oscillator 13.50 78.00

Price Performance

Historical Comparison
PPBT
RDHL

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: